These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38216134)

  • 1. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
    van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
    J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
    Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
    BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
    You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
    Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.
    Oufkir N; Rouzier R; Paoletti X; Bonneau C
    J Ovarian Res; 2024 Jul; 17(1):152. PubMed ID: 39039554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
    Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
    Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
    Colomban O; Clamp A; Cook A; McNeish IA; You B
    JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
    J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
    Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 12. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
    Merlo S; Besic N; Drmota E; Kovacevic N
    Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
    Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
    EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
    Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Matsukuma K; Nishio S; Tasaki S; Park J; Nasu H; Yoshimitsu T; Tasaki K; Katsuda T; Terada A; Tsuda N; Sanada S; Ushijima K
    Kurume Med J; 2024 Jul; 70(1.2):29-37. PubMed ID: 38556270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.